DXCM

SEC source: 0001093557-17-000074 · edgardoc.xml · nonDerivative · entry 1

MOY JEFFREY · CIK 0001446422 · SVP, Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,153

F1 · shares: Shares were transferred from direct ownership to ownership under the Moy Family Trust upon vesting of previously awarded restricted stock units.

F2 · balance_after: Included in this number are 57,216 unvested restricted stock units, 21,883 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 22,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019 and 13,333 of which were granted on March 8, 2015 and shall vest through March 08, 2018.

SEC source: 0001093557-17-000073 · edgardoc.xml · nonDerivative · entry 4

Balo Andrew K · CIK 0001323190 · EVP, Clinical and Regulatory

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 116,033

F3 · shares: These shares were sold to cover the Company's tax withholding obligation that accrued in connection with the vesting of restricted stock units previously granted.

F2 · balance_after: Included in this number are 69,927 unvested restricted stock units, 28,761 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 25,333 of which were granted on March 8, 2016 and shall vest through March 8, 2019 and 15,833 of which were granted on March 8, 2015 and shall vest through March 8, 2018.

SEC source: 0001093557-17-000073 · edgardoc.xml · nonDerivative · entry 3

Balo Andrew K · CIK 0001323190 · EVP, Clinical and Regulatory

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 119,241

F3 · shares: These shares were sold to cover the Company's tax withholding obligation that accrued in connection with the vesting of restricted stock units previously granted.

F2 · balance_after: Included in this number are 69,927 unvested restricted stock units, 28,761 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 25,333 of which were granted on March 8, 2016 and shall vest through March 8, 2019 and 15,833 of which were granted on March 8, 2015 and shall vest through March 8, 2018.

SEC source: 0001093557-17-000073 · edgardoc.xml · nonDerivative · entry 2

Balo Andrew K · CIK 0001323190 · EVP, Clinical and Regulatory

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 125,935

F3 · shares: These shares were sold to cover the Company's tax withholding obligation that accrued in connection with the vesting of restricted stock units previously granted.

F2 · balance_after: Included in this number are 69,927 unvested restricted stock units, 28,761 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 25,333 of which were granted on March 8, 2016 and shall vest through March 8, 2019 and 15,833 of which were granted on March 8, 2015 and shall vest through March 8, 2018.

SEC source: 0001093557-17-000073 · edgardoc.xml · nonDerivative · entry 1

Balo Andrew K · CIK 0001323190 · EVP, Clinical and Regulatory

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 129,463

F1 · shares: On December 09, 2016, Mr. Balo adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Balo. The shares set forth above were sold pursuant to the 10b5-1 Plan.

F2 · balance_after: Included in this number are 69,927 unvested restricted stock units, 28,761 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 25,333 of which were granted on March 8, 2016 and shall vest through March 8, 2019 and 15,833 of which were granted on March 8, 2015 and shall vest through March 8, 2018.

SEC source: 0001093557-17-000081 · edgardoc.xml · derivative · entry 12

Leach Jacob Steven · CIK 0001700255 · SVP, Research & Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 7,500 shares

Expires 2018-05-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001093557-17-000081 · edgardoc.xml · nonDerivative · entry 6

Leach Jacob Steven · CIK 0001700255 · SVP, Research & Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 93,131

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Included in this number are 57,800 unvested restricted stock units, 23,134 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 21,333 of which were granted on March 8, 2016 shall vest through March 8, 2019 and 13,333 of which were granted on March 8, 2015 and shall vest through March 8, 2018.

SEC source: 0001093557-17-000081 · edgardoc.xml · nonDerivative · entry 5

Leach Jacob Steven · CIK 0001700255 · SVP, Research & Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 85,631

F2 · shares: These shares were sold to cover the Company's tax withholding obligation that accrued in connection with the vesting of restricted stock units previously granted.

F1 · balance_after: Included in this number are 57,800 unvested restricted stock units, 23,134 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 21,333 of which were granted on March 8, 2016 shall vest through March 8, 2019 and 13,333 of which were granted on March 8, 2015 and shall vest through March 8, 2018.

SEC source: 0001093557-17-000081 · edgardoc.xml · nonDerivative · entry 4

Leach Jacob Steven · CIK 0001700255 · SVP, Research & Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 88,169

F2 · shares: These shares were sold to cover the Company's tax withholding obligation that accrued in connection with the vesting of restricted stock units previously granted.

F1 · balance_after: Included in this number are 57,800 unvested restricted stock units, 23,134 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 21,333 of which were granted on March 8, 2016 shall vest through March 8, 2019 and 13,333 of which were granted on March 8, 2015 and shall vest through March 8, 2018.

SEC source: 0001093557-17-000081 · edgardoc.xml · nonDerivative · entry 3

Leach Jacob Steven · CIK 0001700255 · SVP, Research & Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 93,642

F2 · shares: These shares were sold to cover the Company's tax withholding obligation that accrued in connection with the vesting of restricted stock units previously granted.

F1 · balance_after: Included in this number are 57,800 unvested restricted stock units, 23,134 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 21,333 of which were granted on March 8, 2016 shall vest through March 8, 2019 and 13,333 of which were granted on March 8, 2015 and shall vest through March 8, 2018.

SEC source: 0001093557-17-000065 · edgardoc.xml · derivative · entry 6

LISTER JOHN · CIK 0001464741 · General Manager, EMEA

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,939

Underlying: Common Stock · 3,000 shares

Expires 2018-01-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001093557-17-000065 · edgardoc.xml · nonDerivative · entry 3

LISTER JOHN · CIK 0001464741 · General Manager, EMEA

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 93,732

F3 · shares: On December 13, 2016, Mr. Lister adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Lister. The shares set forth above were sold pursuant to the 10b5-1 Plan.

F4 · price: This transaction was executed in multiple trades at prices ranging from $77.19 to $78.02. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

F2 · balance_after: Included in this number are 67,634 unvested restricted stock units, 23,134 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 32,000 of which were granted on June 30, 2016 and shall vest through March 8, 2019 and 12,500 of which were granted on March 8, 2015 and shall vest through March 8, 2018.

SEC source: 0001093557-17-000065 · edgardoc.xml · nonDerivative · entry 2

LISTER JOHN · CIK 0001464741 · General Manager, EMEA

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 96,732

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001093557-17-000081 · edgardoc.xml · nonDerivative · entry 2

Leach Jacob Steven · CIK 0001700255 · SVP, Research & Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 95,592

F1 · balance_after: Included in this number are 57,800 unvested restricted stock units, 23,134 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 21,333 of which were granted on March 8, 2016 shall vest through March 8, 2019 and 13,333 of which were granted on March 8, 2015 and shall vest through March 8, 2018.

SEC source: 0001093557-17-000081 · edgardoc.xml · nonDerivative · entry 1

Leach Jacob Steven · CIK 0001700255 · SVP, Research & Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 98,604

F1 · balance_after: Included in this number are 57,800 unvested restricted stock units, 23,134 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 21,333 of which were granted on March 8, 2016 shall vest through March 8, 2019 and 13,333 of which were granted on March 8, 2015 and shall vest through March 8, 2018.

SEC source: 0001093557-17-000068 · edgardoc.xml · nonDerivative · entry 1

DOUBLEDAY RICHARD · CIK 0001466545 · EVP, Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 111,244

F1 · balance_after: Included in this number are 68,676 unvested restricted stock units, 27,510 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 25,333 of which were granted on March 8, 2016 and shall vest through March 8, 2019 and 15,833 of which were granted on March 8, 2015 and shall vest through March 8, 2018.

SEC source: 0001093557-17-000066 · edgardoc.xml · nonDerivative · entry 1

Pacelli Steven Robert · CIK 0001359098 · EVP, Strategy & Corp. Dev.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 137,919

F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting over a 36 month period from the date of grant as follows: 1/3 shall vest 12 months from the Grant Date, and the remaining balance shall vest in four equal installments over the following 24 months. Share units represent a contingent right to receive one share of DexCom, Inc. common stock.

F2 · balance_after: Included in this number are 67,843 unvested restricted stock units, 27,510 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 25,333 of which were granted on March 8, 2016 and shall vest through March 8, 2019 and 15,000 of which were granted on March 8, 2015 and shall vest through March 8, 2019.

SEC source: 0001093557-17-000067 · edgardoc.xml · nonDerivative · entry 1

MOY JEFFREY · CIK 0001446422 · SVP, Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 83,487

F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting over a 36 month period from the date of grant as follows: 1/3 shall vest 12 months from the Grant Date, and the remaining balance shall vest in four equal installments over the following 24 months. Share units represent a contingent right to receive one share of DexCom, Inc. common stock.

F2 · balance_after: Included in this number are 57,216 unvested restricted stock units, 21,883 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 22,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019 and 13,333 of which were granted on March 8, 2015 and shall vest through March 08, 2018.

SEC source: 0001093557-17-000065 · edgardoc.xml · nonDerivative · entry 1

LISTER JOHN · CIK 0001464741 · General Manager, EMEA

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 93,732

F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting over a 36 month period from the date of grant as follows: 1/3 shall vest 12 months from the Grant Date, and the remaining balance shall vest in four equal installments over the following 24 months. Share units represent a contingent right to receive one share of DexCom, Inc. common stock.

F2 · balance_after: Included in this number are 67,634 unvested restricted stock units, 23,134 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 32,000 of which were granted on June 30, 2016 and shall vest through March 8, 2019 and 12,500 of which were granted on March 8, 2015 and shall vest through March 8, 2018.

SEC source: 0001093557-17-000064 · edgardoc.xml · nonDerivative · entry 3

SAYER KEVIN R · CIK 0001286858 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 351,607

F3 · shares: These shares were sold to cover the Company's tax withholding obligation that accrued in connection with the vesting of restricted stock units previously granted.

F2 · balance_after: Included in this number are 171,280 unvested restricted stock units, 81,280 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 60,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019 and 30,000 of which were granted on March 8, 2015 and shall vest through March 8, 2018.

SEC source: 0001093557-17-000064 · edgardoc.xml · nonDerivative · entry 2

SAYER KEVIN R · CIK 0001286858 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 367,460

F3 · shares: These shares were sold to cover the Company's tax withholding obligation that accrued in connection with the vesting of restricted stock units previously granted.

F2 · balance_after: Included in this number are 171,280 unvested restricted stock units, 81,280 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 60,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019 and 30,000 of which were granted on March 8, 2015 and shall vest through March 8, 2018.

SEC source: 0001093557-17-000064 · edgardoc.xml · nonDerivative · entry 1

SAYER KEVIN R · CIK 0001286858 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 380,671

F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting over a 36 month period from the date of grant as follows: 1/3 shall vest 12 months from the Grant Date, and the remaining balance shall vest in four equal installments over the following 24 months. Share units represent a contingent right to receive one share of DexCom, Inc. common stock.

F2 · balance_after: Included in this number are 171,280 unvested restricted stock units, 81,280 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 60,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019 and 30,000 of which were granted on March 8, 2015 and shall vest through March 8, 2018.

SEC source: 0001093557-17-000063 · edgardoc.xml · nonDerivative · entry 1

GREGG TERRANCE H · CIK 0001236388 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 470,732

F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting over a 36 month period from the date of grant as follows: 1/3 shall vest 12 months from the Grant Date, and the remaining balance shall vest in four equal installments over the following 24 months. Share units represent a contingent right to receive one share of DexCom, Inc. common stock.

F2 · balance_after: Included in this number are 30,877 unvested restricted stock units which were granted on March 8, 2017 and shall vest on March 8, 2018.

SEC source: 0001093557-17-000062 · edgardoc.xml · nonDerivative · entry 1

Balo Andrew K · CIK 0001323190 · EVP, Clinical and Regulatory

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 132,663

F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting over a 36 month period from the date of grant as follows: 1/3 shall vest 12 months from the Grant Date, and the remaining balance shall vest in four equal installments over the following 24 months. Share units represent a contingent right to receive one share of DexCom, Inc. common stock.

F2 · balance_after: Included in this number are 69,927 unvested restricted stock units, 28,761 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 25,333 of which were granted on March 8, 2016 and shall vest through March 8, 2019 and 15,833 of which were granted on March 8, 2015 and shall vest through March 8, 2018.

SEC source: 0001093557-17-000061 · edgardoc.xml · nonDerivative · entry 1

Abbey Donald · CIK 0001534342 · EVP Quality

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 82,510

F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting over a 36 month period from the date of grant as follows: 1/3 shall vest 12 months from the Grant Date, and the remaining balance shall vest in four equal installments over the following 24 months. Share units represent a contingent right to receive one share of DexCom, Inc. common stock.

F2 · balance_after: Included in this number are 82,510 unvested restricted stock units, 27,510 of which were granted on March 8, 2017 and shall vest through March 8, 2020 and 55,000 of which were granted on May 31, 2016 and shall vest through May 31, 2019.

SEC source: 0001093557-17-000060 · edgardoc.xml · nonDerivative · entry 1

Murphy Patrick Michael · CIK 0001692785 · VP, Legal Aff & Chf Compl Ofcr

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,489

F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting over a 36 month period from the date of grant as follows: 1/3 shall vest 12 months from the Grant Date, and the remaining balance shall vest in four equal installments over the following 24 months. Share units represent a contingent right to receive one share of DexCom, Inc. common stock.

F2 · balance_after: Included in this number are 25,592 unvested restricted stock units, 11,361 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 10,000 of which were granted on March 8, 2016 shall vest through March 8, 2019 and 4,231 of which were granted on March 8, 2015 and shall vest through March 8, 2018.

SEC source: 0001093557-17-000050 · edgardoc.xml · derivative · entry 5

SKYLER JAY S · CIK 0001236386 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · by Partnership

Disclosed balance after: 0

Underlying: Common Stock · 31,890 shares

Expires 2017-05-23

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001093557-17-000050 · edgardoc.xml · nonDerivative · entry 2

SKYLER JAY S · CIK 0001236386 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · by Partnership

Disclosed balance after: 17,246

F2 · price: This transaction was executed in multiple trades at prices ranging from $78.00 to $78.28. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

F1 · ownership.nature: Shares are held by Skyler Bach Family Limited Partnership, LLP, with respect to which the reporting person is a managing partner of the partnership and maintains voting rights of these shares.

SEC source: 0001093557-17-000050 · edgardoc.xml · nonDerivative · entry 1

SKYLER JAY S · CIK 0001236386 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · by Partnership

Disclosed balance after: 49,136

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · ownership.nature: Shares are held by Skyler Bach Family Limited Partnership, LLP, with respect to which the reporting person is a managing partner of the partnership and maintains voting rights of these shares.

SEC source: 0001093557-17-000037 · edgardoc.xml · nonDerivative · entry 1

DOUBLEDAY RICHARD · CIK 0001466545 · EVP, Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · by Trust

Disclosed balance after: 12,733

F1 · shares: On June 15, 2016, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan.

F2 · price: This transaction was executed in multiple trades at prices ranging from $78.00 to $79.02. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

F3 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee.

SEC source: 0001093557-17-000036 · edgardoc.xml · nonDerivative · entry 1

ROPER JESS · CIK 0001408993 · SVP, CFO

10b5-1 filing: Not disclosed

Ownership: Indirect · by Trust

Disclosed balance after: 10,452

F1 · shares: On November 04, 2016, Mr. Roper adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Roper. The shares set forth above were sold pursuant to the 10b5-1 Plan.

F2 · price: This transaction was executed in multiple trades at prices ranging from $78.23 to $79.75. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

F3 · balance_after: Shares are held by the LJR Family Trust U/T/A DTD 08/08/2013, with respect to which the reporting person is a trustee.

SEC source: 0001093557-17-000033 · edgardoc.xml · derivative · entry 3

SAYER KEVIN R · CIK 0001286858 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,649

Underlying: Common Stock · 10,000 shares

Expires 2017-11-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001093557-17-000033 · edgardoc.xml · nonDerivative · entry 2

SAYER KEVIN R · CIK 0001286858 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 299,391

F1 · shares: On December 12, 2016, Mr. Sayer adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sayer. The shares set forth above were sold pursuant to the 10b5-1 Plan.

F2 · price: This transaction was executed in multiple trades at prices ranging from $80.64 to $82.10. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

F3 · balance_after: Included in this number are 160,000 unvested restricted stock units, 90,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019, 45,000 of which were granted on March 8, 2015 and shall vest through March 8, 2018 and 25,000 of which were granted on March 8, 2014 and shall vest through March 8, 2017.

SEC source: 0001093557-17-000033 · edgardoc.xml · nonDerivative · entry 1

SAYER KEVIN R · CIK 0001286858 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 309,391

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001093557-17-000031 · edgardoc.xml · derivative · entry 4

Balo Andrew K · CIK 0001323190 · EVP, Clinical and Regulatory

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 727 shares

Expires 2020-03-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001093557-17-000031 · edgardoc.xml · nonDerivative · entry 3

Balo Andrew K · CIK 0001323190 · EVP, Clinical and Regulatory

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 103,872

F1 · shares: On December 09, 2016, Mr. Balo adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Balo. The shares set forth above were sold pursuant to the 10b5-1 Plan.

F2 · balance_after: Included in this number are 70,084 unvested restricted stock units, 38,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019, 23,750 of which were granted on March 8, 2015 and shall vest through March 8, 2018 and 8,334 of which were granted on March 8, 2014 and shall vest through March 8, 2017.

SEC source: 0001093557-17-000031 · edgardoc.xml · nonDerivative · entry 2

Balo Andrew K · CIK 0001323190 · EVP, Clinical and Regulatory

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 106,345

F1 · shares: On December 09, 2016, Mr. Balo adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Balo. The shares set forth above were sold pursuant to the 10b5-1 Plan.

F2 · balance_after: Included in this number are 70,084 unvested restricted stock units, 38,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019, 23,750 of which were granted on March 8, 2015 and shall vest through March 8, 2018 and 8,334 of which were granted on March 8, 2014 and shall vest through March 8, 2017.

SEC source: 0001093557-17-000031 · edgardoc.xml · nonDerivative · entry 1

Balo Andrew K · CIK 0001323190 · EVP, Clinical and Regulatory

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 107,072

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001093557-17-000029 · edgardoc.xml · derivative · entry 3

LISTER JOHN · CIK 0001464741 · General Manager, EMEA

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,939

Underlying: Common Stock · 3,000 shares

Expires 2018-01-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001093557-17-000029 · edgardoc.xml · nonDerivative · entry 2

LISTER JOHN · CIK 0001464741 · General Manager, EMEA

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,598

F1 · shares: On December 13, 2016, Mr. Lister adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Lister. The shares set forth above were sold pursuant to the 10b5-1 Plan.

F2 · price: This transaction was executed in multiple trades at prices ranging from $79.41 to $80.32. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

F3 · balance_after: Included in this number are 61,584 unvested restricted stock units, 32,000 of which were granted on June 30, 2016 and shall vest through March 8, 2019, 18,750 of which were granted on March 8, 2015 and shall vest through March 8, 2018 and 10,834 of which were granted on March 8, 2014 and shall vest through March 8, 2017.

SEC source: 0001093557-17-000029 · edgardoc.xml · nonDerivative · entry 1

LISTER JOHN · CIK 0001464741 · General Manager, EMEA

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 73,598

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001093557-17-000027 · edgardoc.xml · nonDerivative · entry 1

GREGG TERRANCE H · CIK 0001236388 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 439,845

F1 · shares: These shares were sold to cover the Company's tax withholding obligation that accrued in connection with the vesting of restricted stock units previously granted.

F2 · balance_after: Included in this number are 39,079 unvested restricted stock units, 34,000 of which were granted on March 8, 2016 and will vest on March 8, 2017 and 5,079 unvested restricted stock units granted on March 8, 2014 and shall vest on March 8, 2017.

SEC source: 0001093557-17-000028 · edgardoc.xml · derivative · entry 4

VALDES JORGE A · CIK 0001343856 · CTO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 7,000 shares

Expires 2020-03-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001093557-17-000028 · edgardoc.xml · nonDerivative · entry 2

VALDES JORGE A · CIK 0001343856 · CTO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 72,334

F1 · shares: On November 4, 2016 Mr. Valdes adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Valdes. The shares set forth above were sold pursuant to the 10b5-1 Plan.

F2 · price: This transaction was executed in multiple trades at prices ranging from $79.40 to $80.48. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

F3 · balance_after: Included in this number are 72,334 unvested restricted stock units, 38,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019, 22,500 of which were granted on March 8, 2015 and shall vest through March 8, 2018 and 11,834 of which were granted on March 8, 2014 and shall vest through March 8, 2017.

SEC source: 0001093557-17-000028 · edgardoc.xml · nonDerivative · entry 1

VALDES JORGE A · CIK 0001343856 · CTO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 79,334

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001093557-17-000023 · edgardoc.xml · derivative · entry 4

VALDES JORGE A · CIK 0001343856 · CTO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,000

Underlying: Common Stock · 13,900 shares

Expires 2020-03-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001093557-17-000023 · edgardoc.xml · nonDerivative · entry 2

VALDES JORGE A · CIK 0001343856 · CTO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 72,334

F1 · shares: On November 4, 2016 Mr. Valdes adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Valdes. The shares set forth above were sold pursuant to the 10b5-1 Plan.

F2 · balance_after: Included in this number are 72,334 unvested restricted stock units, 38,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019, 22,500 of which were granted on March 8, 2015 and shall vest through March 8, 2018 and 11,834 of which were granted on March 8, 2014 and shall vest through March 8, 2017.

SEC source: 0001093557-17-000023 · edgardoc.xml · nonDerivative · entry 1

VALDES JORGE A · CIK 0001343856 · CTO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 86,234

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001093557-17-000021 · edgardoc.xml · nonDerivative · entry 1

DOUBLEDAY RICHARD · CIK 0001466545 · EVP, Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · by Trust

Disclosed balance after: 15,915

F1 · shares: On June 15, 2016, Mr. Doubleday adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Doubleday. The shares set forth above were sold pursuant to the 10b5-1 Plan.

F2 · price: This transaction was executed in multiple trades at prices ranging from $79.01 to $79.76. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

F3 · ownership.nature: Shares are held by the Doubleday Living Trust U/A/D 5/26/2015, with respect to which the reporting person is a trustee.

SEC source: 0001093557-17-000020 · edgardoc.xml · derivative · entry 3

Pacelli Steven Robert · CIK 0001359098 · EVP, Strategy & Corp. Dev.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 9,637 shares

Expires 2017-08-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.